A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion
study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554. This study is to assess the
tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in
participants with relapsed or refractory mature lymphoid neoplasms.